OA12609A - An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. - Google Patents

An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. Download PDF

Info

Publication number
OA12609A
OA12609A OA1200300303A OA1200300303A OA12609A OA 12609 A OA12609 A OA 12609A OA 1200300303 A OA1200300303 A OA 1200300303A OA 1200300303 A OA1200300303 A OA 1200300303A OA 12609 A OA12609 A OA 12609A
Authority
OA
OAPI
Prior art keywords
amino
alkyl
adenosine
sait
diphenylethyl
Prior art date
Application number
OA1200300303A
Other languages
English (en)
Inventor
Roisin A Armstrong
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12609A publication Critical patent/OA12609A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200300303A 2001-05-25 2002-05-24 An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. OA12609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
OA12609A true OA12609A (en) 2006-06-09

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300303A OA12609A (en) 2001-05-25 2002-05-24 An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.

Country Status (22)

Country Link
US (1) US20040171576A1 (es)
EP (1) EP1395287A1 (es)
KR (1) KR20030097901A (es)
CN (1) CN1535161A (es)
AP (1) AP2003002911A0 (es)
BG (1) BG108383A (es)
BR (1) BR0209986A (es)
CA (1) CA2448086A1 (es)
CO (1) CO5540324A2 (es)
CZ (1) CZ20033126A3 (es)
EE (1) EE200300586A (es)
HU (1) HUP0400029A2 (es)
IL (1) IL158774A0 (es)
MA (1) MA27028A1 (es)
MX (1) MXPA03010787A (es)
NO (1) NO20035202D0 (es)
OA (1) OA12609A (es)
PA (1) PA8546101A1 (es)
PL (1) PL366899A1 (es)
SK (1) SK14302003A3 (es)
SV (1) SV2003001055A (es)
WO (1) WO2002096462A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) * 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
EP1121372B1 (en) * 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
BG108383A (bg) 2004-08-31
WO2002096462A1 (en) 2002-12-05
NO20035202D0 (no) 2003-11-24
CZ20033126A3 (cs) 2004-09-15
MXPA03010787A (es) 2004-03-02
CA2448086A1 (en) 2002-12-05
CN1535161A (zh) 2004-10-06
PL366899A1 (en) 2005-02-07
KR20030097901A (ko) 2003-12-31
HUP0400029A2 (hu) 2004-04-28
US20040171576A1 (en) 2004-09-02
EP1395287A1 (en) 2004-03-10
SV2003001055A (es) 2003-11-14
PA8546101A1 (es) 2003-12-10
BR0209986A (pt) 2004-04-06
EE200300586A (et) 2004-04-15
MA27028A1 (fr) 2004-12-20
AP2003002911A0 (en) 2003-12-31
SK14302003A3 (sk) 2004-08-03
CO5540324A2 (es) 2005-07-29
IL158774A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
OA12609A (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
US7107985B2 (en) Pharmaceutical combination
OA12610A (en) A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
AU2002351066B2 (en) Pharmaceutical combinations of adenosine A-2a and beta-2-adrenergic receptor agonists
US20030109485A1 (en) Pharmaceutical combination
NZ533030A (en) Combination of a selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist
AU2002316924A1 (en) An adenosine A2A receptor agonist and an anticholiergic agent in combination for treating obstructive airways diseases
AU2002344167A1 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200308602B (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.